Immunological evaluation of personalized peptide vaccination for patients with histologically unfavorable carcinoma of unknown primary site.

导出 OA

翻译打印收藏纠错

作者： Shinjiro,Sakamoto ^[1] ; Shigeru,Yutani ^[2] ; Shigeki,Shichijo ^[3] ; Michi,Morita ^[1] ; Akira,Yamada ^[1] ; Kyogo,Itoh ^[4] ; Masanori,Noguchi ^[5]

作者单位： Cancer Vaccine Center, Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Japan. ^[1] Clinical Research Division, Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, 830-0011, Japan. ^[2] Department of Molecular and Internal Medicine, Hiroshima University School of Medicine, Hiroshima, Japan. ^[3] Department of Surgery, Nagasaki University Graduate Biomedical Science, Nagasaki, Japan. ^[4] Cancer Vaccine Division, Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Japan. ^[5] Cancer Vaccine Center, Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Japan. noguchi@med.kurume-u.ac.jp. ^[6] Clinical Research Division, Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, 830-0011, Japan. noguchi@med.kurume-u.ac.jp. ^[7]

关键词 Cancer immunotherapy Carcinoma of unknown primary site Metastasis Personalized peptide vaccine Unfavorable subsets